Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor

• Material Type: 博士論文
• Title: Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor
• Author/Editor: 本川, 哲史
• Author Heading: 本川, 哲史
• Publication, Distribution, etc.: The Japanese Circulation Society
• Publication Date: 2022-03-18
• Publication Date (W3CDTF): 2022-03-18
• Alternative Title: 慢性骨髄性白血病および消化管間質腫瘍(GIST)の日本人患者におけるダサチニブおよびイマチニブに関連する心毒性有害事象の比較
• Periodical title: Circulation Reports
• No. or year of volume/issue: 4 1
• Volume: 4
• Issue: 1
• Pages: 1-8
• ISSN (Periodical Title): ISSN : 2434-0790
• Degree grantor/type: Nagasaki University (長崎大学)
• Date Granted: 2022-03-18
• Dissertation Number: 甲医歯薬第1422号
• Degree Type: 博士(医学)
• Text Language Code: eng
• Subject Heading: Cardiotoxicity; Congestive heart failure; Pleural effusion; Pulmonary hypertension; QT prolongation
• Target Audience: 一般
• Note (General): Background: Despite the beneficial effects ofBCR-ABL1tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML), they may also cause adverse events (AEs), especially cardiovascular toxicity. The incidence of TKI-induced AEs may vary among ethnic groups, and there is little specific information for Japanese patients.Methods and Results: Sixty-nine consecutive patients who were started on treatment with dasatinib (n=25) or imatinib (n=44) for CML or gastrointestinal stromal tumor (GIST) between December 2008 and December 2019 were retrospectively recruited to the study. We determined the prevalence of AEs through October 2020 and compared the incidence of AEs between the 2 drugs. Baseline characteristics were comparable between the 2 groups. However, compared with the imatinib-treated group, the dasatinib-treated group had a higher incidence of congestive heart failure (CHF; 20.0% vs. 2.3%; P=0.04), pleural effusion (48% vs. 20.5%; P=0.03), pericardial effusion (24% vs. 4.6%; P=0.02), QT prolongation (4 vs. 0 patients; P=0.02), and pulmonary hypertension (3 vs. 0 patients; P=0.04). In the dasatinib-treated group, CHF tended to be associated with tricuspid valve regurgitation pressure gradient, and pleural effusion was observed in all patients. All-cause mortality and other cardiovascular events did not differ significantly between the 2 groups.Conclusions: Cardiotoxic AEs occurred more frequently in Japanese patients with CML and GIST treated with dasatinib than imatinib.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第1422号 学位授与年月日:令和4年3月18日; Author: Tetsufumi Motokawa,Satoshi Ikeda,Yuki Ueno,Masamichi Eguchi,Takako Minami,Hiroaki Kawano,Kazuma Kobayashi,Yoshitaka Imaizumi,Koji Maemura; Citation: Circulation Reports, 4(1), pp. 1-8; 2022; identifier:Nagasaki University (長崎大学), 博士(医学) (2022-03-18)
• Source: https://nagasaki-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=27814&item_no=1&attribute_id=70&file_no=1 （fulltext）; https://nagasaki-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=27814&item_no=1&attribute_id=70&file_no=1
• Access Restrictions: インターネット公開
• Rights (production): © 2022, THE JAPANESE CIRCULATION SOCIETY
• Related Material: http://hdl.handle.net/10069/00041425
• Related Material (DOI): 10.1253/circrep.CR-21-0140
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 長崎大学 : 長崎大学学術研究成果リポジトリ